$0.07
2.78% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US71678J1007
Symbol
PTPI
Sector
Industry

Petros Pharmaceuticals Inc Stock price

$0.07
-0.03 27.86% 1M
-0.27 79.13% 6M
-0.32 81.72% YTD
-1.00 93.27% 1Y
-13.73 99.48% 3Y
-41.43 99.83% 5Y
-1,791.93 100.00% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.01 14.29%
ISIN
US71678J1007
Symbol
PTPI
Sector
Industry

Key metrics

Market capitalization $2.15m
Enterprise Value $5.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.14
P/S ratio (TTM) P/S ratio 0.42
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $5.11m
EBIT (operating result TTM) EBIT $-10.30m
Free Cash Flow (TTM) Free Cash Flow $-2.63m
Cash position $3.71m
EPS (TTM) EPS $-3.62
P/S forward 0.57
EV/Sales forward 0.81
Short interest 2.68%
Show more

Is Petros Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Petros Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

Buy
100%

Financial data from Petros Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5.11 5.11
-
100%
- Direct Costs 4.04 4.04
-
79%
1.07 1.07
-
21%
- Selling and Administrative Expenses 5.81 5.81
-
114%
- Research and Development Expense 2.62 2.62
-
51%
-7.35 -7.35
-
-144%
- Depreciation and Amortization 2.94 2.94
-
58%
EBIT (Operating Income) EBIT -10 -10
-
-201%
Net Profit -14 -14
-
-280%

In millions USD.

Don't miss a Thing! We will send you all news about Petros Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Petros Pharmaceuticals Inc Stock News

Neutral
Accesswire
14 days ago
Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through ov...
Neutral
Accesswire
about one month ago
Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces top-line resu...
Neutral
Accesswire
about one month ago
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces the pricing of a public offering of approximately 40,000,000 shares of the Company's common stock ("Common Stock"), par value $0.0001 p...
More Petros Pharmaceuticals Inc News

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics. Its commercial capabilities include sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The firm operates through Prescription Medications and Medical Devices segments. The Prescription Medications segment consists primarily of Stendra, which is sold generally in the United States. The Medical Devices segment includes vacuum erection devices, which are sold domestically and internationally. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Head office United States
CEO John Shulman
Employees 18
Website www.petrospharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today